Reaction to the Historic Approval of RBX2660
RBX2660 is the first ever live microbiota therapeutic approved by the FDA.
Bad Bugs, New Drugs: A Discussion of Selected New Therapeutics From IDWeek 2022
Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.
Infectious Diseases and Therapy on Twitter
Read the final report from the phase 2b PUNCH CD2 study of RBX2660, an investigational live biotherapeutic to reduce C. difficile infection recurrence, showing 24-month safety and meaningful efficacy for 1 dose v placebo - https://t.co/hyVJ0cABVR#cdiff #microbiome— Infectious Diseases and Therapy (@InfectDis_Ther) December 22, 2022
An insight into the Clostridioides difficile infection-related diarrhea - PubMed
An insight into the Clostridioides difficile infection-related diarrhea
Antimicrobial Activity of Tannic Acid In Vitro and Its Protective Effect on Mice against Clostridioides difficile - PubMed
Clostridioides difficile infection (CDI), recurrently reported as an urgent threat owing to its increased prevalence and mortality, has attracted significant attention. As the use of antibiotics to treat CDI has many limitations, such as high recurrence rate, the need to actively seek and develop ot …
Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection - PubMed
ClinicalTrials.gov: NCT02299570.
Global Microbiome Therapeutics Market Report 2022 - Players Include Evelo Biosciences, Ferring International, Immuron and LNC Therapeutics
Dublin, Dec. 20, 2022 (GLOBE NEWSWIRE) -- The "Microbiome Therapeutics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Microbiome
FDA PDUFA Date Set for C diff Drug, SER-109
The US FDA has accepted a Biologics License Application (BLA) for Seres Therapeutics' SER-109, and set a Prescription Drug User Fee Act (PDUFA) action date of April 26, 2023.
BiomeBank Continues Growth Trajectory With Over $10M Capital Raise - Business Wire
Oral Microbiome Therapeutic Gets Priority Review for Recurrent C difficile Infection
SER-109 contains purified bacterial spores of multiple Firmicute species obtained from the stool of healthy human donors.
Clostridium Difficile Infections Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
With a Massive CAGR of 25%, Human Microbiome Market Size to surpass US$ 442.37 billion by 2030
Pune, Dec. 09, 2022 (GLOBE NEWSWIRE) -- According to a new market research report titled, “Human Microbiome Market by Product (Probiotics, Prebiotics,...
Nicholas Meyer on Twitter
“#cdiff folks, if you are diagnosed with c-diff then look into enrolling in acurx phase 2 trial. 100% cure rate in phase 2a and showed a microbiome response that has never been seen before in history of c-diff antibiotics”
New Therapeutic Offers Promise for Recurrent C Diff Infection
An easy-to-administer oral biologic kept repeat C difficile infections at bay in a new study.
FDA Approves First Fecal Microbiota Product | FDA
The FDA approved the first fecal microbiota product, Rebyota, for the prevention of recurrence of CDI in adults.
MTIG on Twitter
#MicrobiomeTherapeutics have potential to restore microbial diversity to prevent #CDiff spore germination & disease without the complications of antibiotics. Learn about @Rebiotix, @SeresTX & @VedantaBio's work to develop microbiome therapeutics for CDI: https://t.co/dXa0aXsMUb— MTIG (@MTIG_News) December 6, 2022
FDA Approval of First Fecal Microbiota Product Ensures Safety in Standardization: Ferring Chief Scientific Officer Dr. Elizabeth Garner explains the FDA approval of recurrent C diff treatment RBX2660 provides more than a treatment… https://t.co/yzGZzeZa
FDA Approval of First Fecal Microbiota Product Ensures Safety in Standardization: Ferring Chief Scientific Officer Dr. Elizabeth Garner explains the FDA approval of recurrent C diff treatment RBX2660 provides more than a treatment… https://t.co/yzGZzeZaWR #cdiff #cdi #fmt— Dave Roberts (@CDifficile1) December 8, 2022
FDA Greenlights First Fecal Microbiota Product | MedPage Today
Rebyota approved for preventing recurrence of C. difficile infection
Expanding Government Assistance is Controlling the Market, Microbiome Therapeutics Market to Grow By 32% CAGR through 2032, Says Fact.MR - GlobeNewswire
Improved Microbiome Sequencing Capabilities are Likely to Boost the Microbiome Therapeutics Market...
Looking Beyond C difficile: The Potential of the Gut Microbiome - Contagionlive.com
Dr. Elizabeth Garner speculates the FDA approval of RBX2660 for recurrent C difficile infection will pave the way for more restorative microbiome therapies.
Seeking therapeutic opportunities amid the complexity of the microbiome
Companies developing microbiome-based therapies have been beset by challenges in the past few years, but hopes remain for some applications and could soon be boosted by the first regulatory approval in the field.
US FDA approves Ferring's Rebyota for Clostridioides difficile infection - Pharmaceutical Technology
The US FDA has granted approval for Ferring Pharmaceuticals’ Rebyota to prevent Clostridioides difficile infection recurrence.
Using Immunoinformatics to Create a Clostridium Difficile Vaccine - Pharmacy Times
Immunoinformatics allows researchers to develop vaccines without microbial culturing, thus saving time and money.
SER-109, CP101, VE303 for Treatment of Recurrent C. difficile Infection (rCDI) - Pharmacy Times
Drs Abraham and Feuerstadt share recent data with emerging live biotherapeutic products, SER-109, CP101, and VE303, for treatment of recurrent C difficile infection (rCDI).
Global Microbiome Therapeutics Market Report 2022: Mergers and Collaborations Continue to Boost Brand New Industry - ResearchAndMarkets.com - Business Wire
Clostridium Difficile Diagnostics Market to Surpass US$ 1,450.29 Mn with a CAGR of 7.1% by 2030 | Abbott Laboratories - Medgadget
Clostridium Difficile Infections Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companies, Growth Prospects and Future Clostridium Difficile Infections Pipeline Landscape - Digital Journal
DelveInsight’s, “Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route […]
Insights into the Spectrum of Activity and Mechanism of Action of MGB-BP-3
MGB-BP-3 is a potential first-in-class antibiotic, a Strathclyde Minor Groove Binder (S-MGB), that has successfully completed Phase IIa clinical trials for the treatment of Clostridioides difficile associated disease. Its precise mechanism of action and the origin of limited activity against …
Clostridium Difficile Infection Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies – Summit Therapeutics, Merck Sharp & Dohme LLC, Astellas Pharma Inc., Acurx Pharmaceuticals Inc., a - Digit
(Nevada, USA) DelveInsight’s “Clostridium Difficile Infection Market Insight, Epidemiology and Market Forecast – 2032” report provides current treatment practices, emerging drugs, Clostridium Difficile Infection market share of the individual therapies, current and forecasted Clostridium Difficile Infection market size from 2019 to 2032 segmented by seven major markets. The report also offers current Clostridium Difficile […]
Redefining genomic view of Clostridioides difficile through pangenome analysis and identification of drug targets from its core genome - PubMed
The suggested potent targets could act as broad-spectrum drug targets for C. difficile. However, further validation needs to be done before using them for lead compound discovery.